Trials / Completed
CompletedNCT00421655
A Trial of Grazax in Subjects With Hayfever
A Phase III Trial Assessing the Efficacy and Safety of Grazax in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 329 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The trial is performed to evaluate the efficacy and safety of specific immunotherapy with Grazax for treatment of grass pollen induced allergy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Grazax | Tablets 75,000 SQT and matching placebo. One tablet daily. |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2007-08-01
- Completion
- 2007-10-01
- First posted
- 2007-01-12
- Last updated
- 2015-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00421655. Inclusion in this directory is not an endorsement.